Sellas Life Sciences is trading 7.1% up at $14.70 after renewed attention around an unconfirmed report that the Phase 3 REGAL leukemia trial reached its 80th event.
- Latest official count remains 78 events; no August 27, 2026 company announcement was identified; the catalyst remains speculative.
- Elevated activity followed a rebound from August 26’s $13.73 close after a 2.56% decline; broader risk-on sentiment may support shares.
- Confidence is medium: coverage supports the trial explanation, but official confirmation is absent.